Korea United Pharm Inc. (033270.KS)
KRW 18480.0
(-1.75%)
KRW 18480.0
(-1.75%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 70.78 Billion KRW | -6.26% |
| 2022 | 61.76 Billion KRW | 34.25% |
| 2021 | 46.61 Billion KRW | 6.56% |
| 2020 | 43.26 Billion KRW | -2.32% |
| 2019 | 44.96 Billion KRW | -4.41% |
| 2018 | 47.63 Billion KRW | 41.23% |
| 2017 | 36.16 Billion KRW | -0.44% |
| 2016 | 34.63 Billion KRW | 16.76% |
| 2015 | 32.15 Billion KRW | 2.78% |
| 2014 | 30.94 Billion KRW | 35.89% |
| 2013 | 22.72 Billion KRW | -14.4% |
| 2012 | 25.94 Billion KRW | -6.87% |
| 2011 | 28.39 Billion KRW | 15.77% |
| 2010 | 24.65 Billion KRW | 20.7% |
| 2009 | 20.44 Billion KRW | 30.4% |
| 2008 | 16 Billion KRW | 56.33% |
| 2007 | 10.07 Billion KRW | 4.44% |
| 2006 | 9.64 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | 15.05 Billion KRW | 334.18% |
| 2024 Q1 | 16.86 Billion KRW | 352.69% |
| 2024 Q2 | 12.53 Billion KRW | -124.5% |
| 2023 Q4 | 13.89 Billion KRW | -65.85% |
| 2023 Q3 | 40.67 Billion KRW | -1.32% |
| 2023 Q2 | 41.22 Billion KRW | 5.39% |
| 2023 Q1 | 39.11 Billion KRW | 7701.61% |
| 2023 FY | - KRW | -6.26% |
| 2022 FY | - KRW | 34.25% |
| 2022 Q3 | 30.23 Billion KRW | 35.52% |
| 2022 Q1 | 16.68 Billion KRW | 60.91% |
| 2022 Q2 | 22.31 Billion KRW | 33.76% |
| 2022 Q4 | 501.35 Million KRW | -98.34% |
| 2021 Q3 | 16 Billion KRW | 40.26% |
| 2021 Q4 | 10.36 Billion KRW | -35.25% |
| 2021 Q1 | 14.15 Billion KRW | 60.86% |
| 2021 FY | - KRW | 6.56% |
| 2021 Q2 | 11.41 Billion KRW | -19.35% |
| 2020 Q1 | 16.28 Billion KRW | 31.88% |
| 2020 Q2 | 10.89 Billion KRW | -33.11% |
| 2020 Q3 | 12.77 Billion KRW | 17.27% |
| 2020 Q4 | 8.79 Billion KRW | -31.12% |
| 2020 FY | - KRW | -2.32% |
| 2019 Q1 | 13.34 Billion KRW | -17.14% |
| 2019 Q3 | 13.53 Billion KRW | 26.66% |
| 2019 FY | - KRW | -4.41% |
| 2019 Q4 | 12.34 Billion KRW | -8.75% |
| 2019 Q2 | 10.68 Billion KRW | -19.94% |
| 2018 FY | - KRW | 41.23% |
| 2018 Q4 | 16.1 Billion KRW | 43.11% |
| 2018 Q1 | 12.65 Billion KRW | 243.59% |
| 2018 Q2 | 11.8 Billion KRW | -6.66% |
| 2018 Q3 | 11.25 Billion KRW | -4.72% |
| 2017 Q1 | 7.87 Billion KRW | -27.92% |
| 2017 Q3 | 15.23 Billion KRW | 49.61% |
| 2017 Q2 | 10.18 Billion KRW | 29.34% |
| 2017 FY | - KRW | -0.44% |
| 2017 Q4 | 3.68 Billion KRW | -75.82% |
| 2016 Q2 | 7.36 Billion KRW | -38.61% |
| 2016 Q4 | 10.91 Billion KRW | 41.07% |
| 2016 Q3 | 7.74 Billion KRW | 5.09% |
| 2016 FY | - KRW | 16.76% |
| 2016 Q1 | 11.99 Billion KRW | 0.0% |
| 2015 FY | - KRW | 2.78% |
| 2015 Q4 | - KRW | -100.0% |
| 2015 Q3 | 7.96 Billion KRW | 6.84% |
| 2015 Q2 | 7.45 Billion KRW | -22.48% |
| 2015 Q1 | 9.61 Billion KRW | 23.84% |
| 2014 Q4 | 7.76 Billion KRW | -9.06% |
| 2014 FY | - KRW | 35.89% |
| 2014 Q1 | 8.28 Billion KRW | 57.39% |
| 2014 Q3 | 8.53 Billion KRW | 46.66% |
| 2014 Q2 | 5.81 Billion KRW | -29.76% |
| 2013 Q4 | 5.26 Billion KRW | 17.36% |
| 2013 FY | - KRW | -14.4% |
| 2013 Q1 | 7.7 Billion KRW | 15.28% |
| 2013 Q2 | 5.31 Billion KRW | -31.01% |
| 2013 Q3 | 4.48 Billion KRW | -15.6% |
| 2012 Q3 | 5.17 Billion KRW | -6.07% |
| 2012 Q4 | 6.68 Billion KRW | 29.18% |
| 2012 FY | - KRW | -6.87% |
| 2012 Q1 | 8.78 Billion KRW | 0.0% |
| 2012 Q2 | 5.5 Billion KRW | -37.31% |
| 2011 Q3 | 8.43 Billion KRW | -2.84% |
| 2011 Q2 | 8.68 Billion KRW | 3.53% |
| 2011 FY | - KRW | 15.77% |
| 2011 Q1 | 8.38 Billion KRW | 46.6% |
| 2011 Q4 | - KRW | -100.0% |
| 2010 Q2 | 6.56 Billion KRW | 40.78% |
| 2010 Q1 | 4.65 Billion KRW | 37.21% |
| 2010 Q4 | 5.72 Billion KRW | -24.56% |
| 2010 Q3 | 7.58 Billion KRW | 15.63% |
| 2010 FY | - KRW | 20.7% |
| 2009 Q4 | 3.39 Billion KRW | -23.72% |
| 2009 FY | - KRW | 30.4% |
| 2009 Q1 | 7.05 Billion KRW | 142.7% |
| 2009 Q2 | 5.54 Billion KRW | -21.34% |
| 2009 Q3 | 4.45 Billion KRW | -19.73% |
| 2008 Q4 | 2.9 Billion KRW | -22.99% |
| 2008 Q2 | 4.51 Billion KRW | 0.49% |
| 2008 Q1 | 4.48 Billion KRW | 0.0% |
| 2008 FY | - KRW | 56.33% |
| 2008 Q3 | 3.77 Billion KRW | -16.38% |
| 2007 Q2 | 3.43 Billion KRW | 0.0% |
| 2007 Q3 | 3.1 Billion KRW | -9.67% |
| 2007 FY | - KRW | 4.44% |
| 2006 FY | - KRW | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -1356.883% |
| Dong-A Socio Holdings Co., Ltd. | 141.36 Billion KRW | 49.93% |
| Ildong Holdings Co., Ltd. | -64.03 Billion KRW | 210.532% |
| HANDOK Inc. | 35.06 Billion KRW | -101.845% |
| Kukje Pharma Co., Ltd. | -1.03 Billion KRW | 6928.284% |
| Yuhan Corporation | 127.43 Billion KRW | 44.457% |
| Dong-A ST Co., Ltd. | 37.52 Billion KRW | -88.641% |
| SAMSUNG PHARM. Co., LTD. | -21.68 Billion KRW | 426.364% |
| Hanmi Pharm. Co., Ltd. | 323.33 Billion KRW | 78.109% |
| Hanall Biopharma Co.,Ltd | 4.99 Billion KRW | -1318.351% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | -368.178% |
| Dong Sung Bio Pharm.Co.,Ltd. | 3.42 Billion KRW | -1969.009% |
| MYUNGMOON Pharm co.,Ltd | 4.52 Billion KRW | -1463.721% |
| Hana Pharm Co., Ltd. | 35.48 Billion KRW | -99.458% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -1356.883% |
| Ilsung Pharmaceuticals Co., Ltd. | -18.47 Billion KRW | 483.18% |
| REYON Pharmaceutical Co., Ltd. | 6.55 Billion KRW | -979.797% |
| Aprogen pharmaceuticals,Inc. | -49.29 Billion KRW | 243.594% |
| JW Holdings Corporation | 187.88 Billion KRW | 62.328% |
| Ildong Pharmaceutical Co., Ltd. | -51.22 Billion KRW | 238.166% |
| Chong Kun Dang Pharmaceutical Corp. | 283.62 Billion KRW | 75.044% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 20.668% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 290.953% |
| Hyundai Pharmaceutical Co., Ltd. | 13.2 Billion KRW | -435.825% |
| Samil Pharmaceutical Co.,Ltd | 11.82 Billion KRW | -498.42% |
| Jeil Pharmaceutical Co.,Ltd | 18.65 Billion KRW | -279.421% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -1356.883% |
| Kwang Dong Pharmaceutical Co., Ltd. | 54.97 Billion KRW | -28.755% |
| Daewoong pharmaceutical Co.,Ltd | 164.91 Billion KRW | 57.08% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 20.668% |
| Yuhan Corporation | 127.43 Billion KRW | 44.457% |
| Jeil Pharma Holdings Inc | 33.47 Billion KRW | -111.436% |
| Yungjin Pharm. Co., Ltd. | 7.64 Billion KRW | -825.253% |
| Suheung Co., Ltd. | 77.02 Billion KRW | 8.111% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 20.668% |
| Samjin Pharmaceuticals Co., Ltd. | 36.63 Billion KRW | -93.207% |
| CKD Bio Corp. | -1.63 Billion KRW | 4441.168% |
| Daewon Pharmaceutical Co., Ltd. | 49.79 Billion KRW | -42.149% |
| Dongwha Pharm.Co.,Ltd | 32.56 Billion KRW | -117.374% |
| Whan In Pharm Co.,Ltd. | 36.81 Billion KRW | -92.284% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 290.953% |
| Chong Kun Dang Holdings Corp. | 62.28 Billion KRW | -13.641% |
| Boryung Corporation | 114.28 Billion KRW | 38.069% |
| Bukwang Pharmaceutical Co., Ltd. | -30.56 Billion KRW | 331.548% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | -368.178% |
| JW Lifescience Corporation | 50.82 Billion KRW | -39.251% |